Shire to acquire New River in $2.6 billion deal

Share this article:
British drugmaker Shire said today it has agreed to buy New River Pharmaceuticals for $2.6 billion or $64 a share in cash. Shire said in published reports the deal will allow the company to capture the full economic value of attention deficit hyperactivity disorder (ADHD) drug Vyvanse and to gain control of the future development and commercialization of the treatment. Shire said the acquisition is in line with its increased focus on the ADHD market. “This is an important and complementary acquisition that gives us full control of Vyvanse, a novel drug,” Shire CEO Matthew Emmens said in a statement. Emmens added that he expects the purchase to add to earnings from late 2009. New River developed Vyvanse, a follow-on ADHD drug that Shire is hoping will replace Adderall, which accounted for more than half of Shire’s third-quarter sales. In January 2005, Shire and New River struck a collaborative agreement to develop and co-promote Vyvanse.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union